Last Price$89.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20

Today's Change0(0.00%)
Bid (Size)$87.80 (1)
Ask (Size)$89.69 (77)
Day Low / HighN/A - N/A
Volume652.0 K

Incyte Says Data Showed Positive Overall Response Rate for Tabrecta in Patients With Non-Small Cell Lung Cancer

3:51AM ET 9/03/2020 MT Newswires
Incyte (INCY) said Wednesday data from a phase 2 study of Tabrecta showed positive overall response rates with durable responses among adults with metastatic non-small cell lung cancer whose tumors have a mutation.

The overall response rate among treatment-naive patients was 68%, while it was 41% among previously treated patients, the company said.

The most common treatment-related adverse events were peripheral edema, nausea and vomiting.

The study was conducted by Novartis (NVS), which has exclusive worldwide development and commercialization rights to Tabrecta. Under the agreement, Incyte is eligible to receive more than $500 million in milestones and 12% to 14% of royalties on global net sales of the drug.

Price: 95.44, Change: +2.47, Percent Change: +2.66